|4Jun 29, 8:57 PM ET

BIOSITE INC 4

4 · BIOSITE INC · Filed Jun 29, 2007

Insider Transaction Report

Form 4
Period: 2007-06-29
HIBBERD CHRISTOPHER R
SVP Bus Dvlpmnt & Strat Plan
Transactions
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2007-06-291,8730 total
    Exercise: $53.38Exp: 2015-06-17Common Stock (1,873 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2007-06-292550 total
    Exercise: $49.15Exp: 2014-10-22Common Stock (255 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2007-06-291,9790 total
    Exercise: $44.18Exp: 2014-06-18Common Stock (1,979 underlying)
  • Disposition from Tender

    Common Stock

    2007-06-29$92.50/sh404$37,3700 total
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2007-06-292,0000 total
    Exercise: $13.88Exp: 2008-05-21Common Stock (2,000 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2007-06-292,2800 total
    Exercise: $44.18Exp: 2014-06-18Common Stock (2,280 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2007-06-293,4950 total
    Exercise: $49.15Exp: 2014-10-22Common Stock (3,495 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2007-06-2915,6270 total
    Exercise: $53.38Exp: 2015-06-17Common Stock (15,627 underlying)
Footnotes (7)
  • [F1]This option, which provided for daily vesting over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 3,583 shares of Inverness common stock for $7.75 per share.
  • [F2]This option, which provided for daily vesting over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 3,545 shares of Inverness common stock for $24.66 per share.
  • [F3]This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 456 shares of Inverness common stock for $27.44 per share.
  • [F4]This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 3,355 shares of Inverness common stock for $29.80 per share.
  • [F5]This option, which provided for daily vesting over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 4,084 shares of Inverness common stock for $24.66 per share.
  • [F6]This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 6,261 shares of Inverness common stock for $27.44 per share.
  • [F7]This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant, was assumed by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness and replaced with an option to purchase 27,997 shares of Inverness common stock for $29.80 per share.

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT